How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?

被引：2
|
作者：
Sorensen, P. S. [1 ]
机构：
[1] Univ Copenhagen Hosp, Rigshosp, Dept Neurol, Danish Multiple Sclerosis Res Ctr, DK-2100 Copenhagen, Denmark
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2009年 / 16卷 / 03期
关键词：
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;
D O I：
10.1111/j.1468-1331.2008.02518.x
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：287 / 288
页数：2
相关论文
共 50 条
  • [1] IS SECOND-LINE IMMUNOMODULATORY TREATMENT EFFECTIVE IN MULTIPLE SCLEROSIS?
    Racz Lilla
    Berenyi Ervin
    Barsi Peter
    Bernath David
    Csepany Tunde
    [J]. IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2017, 70 (7-8): : 275 - 283
  • [2] Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis
    Putzki, N.
    Kollia, K.
    Woods, S.
    Igwe, E.
    Diener, H. C.
    Limmroth, V.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (03) : 424 - 426
  • [3] Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
    Lorscheider, Johannes
    Benkert, Pascal
    Lienert, Carmen
    Hanni, Peter
    Derfuss, Tobias
    Kuhle, Jens
    Kappos, Ludwig
    Yaldizli, Ozgur
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (06) : 777 - 785
  • [4] Are Natalizumab and Fingolimod Analogous Second-Line Options for the Treatment of Relapsing-Remitting Multiple Sclerosis? A Clinical Practice Observational Study
    Gajofatto, Alberto
    Bianchi, Maria Rachele
    Deotto, Luciano
    Benedetti, Maria Donata
    [J]. EUROPEAN NEUROLOGY, 2014, 72 (3-4) : 173 - 180
  • [5] Second-line use of Fingolimod in RRMS is as effective as natalizumab
    Braune, S.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 450 - 450
  • [6] COST MINIMIZATION ANALYSIS OF FINGOLIMOD VERSUS NATALIZUMAB IN THE SECOND-LINE TREATMENT OF REMITTENT-RECURRENT MULTIPLE SCLEROSIS
    Crespo, C.
    Izquierdo, G.
    Garcia-Ruiz, A.
    Granell, M.
    Brosa, M.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A552 - A552
  • [7] Lower relapse rates with natalizumab as compared with fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
    Lienert, C.
    Benkert, P.
    Beer, S.
    Hanni, P.
    Pardini, M.
    D'Souza, M.
    Derfuss, T.
    Kuhle, J.
    Kappos, L.
    Yaldizli, O.
    [J]. SWISS MEDICAL WEEKLY, 2016, 146 : 49S - 49S
  • [8] Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
    Meca-Lallana, Jose
    Ayuso, Teresa
    Martinez-Yelamos, Sergio
    Duran, Carmen
    Contreras Martin, Yessica
    Herrera Navarro, Nicolas
    Perez Sempere, Angel
    Alvarez-Cermeno, Jose C.
    Millan Pascual, Jorge
    Meca-Lallana, Virginia
    Romero Sevilla, Raul
    Ricart, Javier
    [J]. EUROPEAN NEUROLOGY, 2020, 83 (01) : 25 - 33
  • [9] Lower relapse rates with natalizumab as compared with fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
    Lienert, C.
    Benkert, P.
    Beer, S.
    Hanni, P.
    Pardini, M.
    D'Souza, M.
    Derfuss, T.
    Kuhle, J.
    Kappos, L.
    Yaldizli, O.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 627 - 627
  • [10] When should second-line treatment of multiple sclerosis be started?
    Losy, Jacek
    [J]. AKTUALNOSCI NEUROLOGICZNE, 2015, 15 (03): : 124 - 129
12345